People · Operator
Named in public records as an officer, director or promoter · active 2009–2011 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Affymax Inc | — | Biotechnology | Series C | $42.0M | $1.7B | 2009 |
| Kythera Biopharmaceuticals Inc | — | Pharmaceuticals | Series B | $37.4M | $1.3B | 2011 |
| ARYx Therapeutics, Inc. | — | Pharmaceuticals | Seed | $2.4M | $76.6M | 2010 |
Keith Leonard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keith Leonard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| John Walker | 1 | 17 |
| David Schnell | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Nicholas Galakatos | 1 | 6 |
| Camille Samuels | 1 | 6 |
| Ted W. Love | 1 | 5 |
| Arlene Morris | 1 | 5 |
| Paul Goddard | 1 | 4 |
| Hironori Hozoji | 1 | 4 |
| Dennis Fenton | 1 | 4 |
| Joseph Turner | 1 | 4 |
| Francois Kress | 1 | 3 |
| Nathaniel David | 1 | 3 |
| Lars G. Ekman | 1 | 3 |
| Nick Simon | 1 | 3 |
| Lars Ekman | 1 | 2 |
| Paul G. Sekhri | 1 | 2 |
| Daniel Spiegelman | 1 | 2 |
| Steven Love | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.